Race Oncology Gains $5.25M R&D Tax Refund Boost

Race Oncology Ltd. (AU:RAC) has released an update.

Race Oncology Ltd has secured a $5.25 million R&D tax refund from the Australian Taxation Office for FY2024, thanks to the government’s incentive program. This funding will support the company’s efforts to accelerate the clinical development of its cancer treatment, RC220, which aims to meet significant unmet patient needs. Race Oncology is actively exploring partnerships to enhance global access to its innovative cancer therapies.

For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.